Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 35.61 USD 2.24% Market Closed
Market Cap: 10.2B USD
Have any thoughts about
Exelixis Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

14
Current
18.2
Median
4.2
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
14
=
Enterprise Value
8.9B USD
/
EBITDA
636m USD
All Countries
Close
Market Cap EV/EBITDA
US
Exelixis Inc
NASDAQ:EXEL
10.1B USD 14
FR
Pharnext SCA
OTC:PNEXF
6T USD -218 674.5
US
Abbvie Inc
NYSE:ABBV
314.7B USD 15.4
US
Amgen Inc
NASDAQ:AMGN
157B USD 17.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 24
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -516.7
AU
CSL Ltd
ASX:CSL
133.6B AUD 20.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 16.2
US
Seagen Inc
F:SGT
39.3B EUR -59
NL
argenx SE
XBRU:ARGX
34.5B EUR -105.1
EBITDA Growth
US
Exelixis Inc
NASDAQ:EXEL
Average EV/EBITDA: 16.7
14
261%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.4
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
13.7
2-Years Forward
EV/EBITDA
14.2
3-Years Forward
EV/EBITDA
12.6

See Also

Discover More